[Kangyuan Pharmaceutical Company and related personnel receive warning letter from Jiangsu Securities Regulatory Bureau] Financial Associated Press, May 15, Kangyuan Pharmaceutical Industry announcement, the company and related personnel recently received a warning letter from Jiangsu Securities Regulatory Bureau. According to the investigation, the company's annual report in 2019 falsely increased R & D expenses by 10.5 million yuan, accounting for 1.82% of the total profits of the consolidated statement in the current period. Yin Honggang, then Chief Financial Officer and Secretary of the Board of Directors, failed to perform his duties faithfully and diligently and was primarily responsible for the above violations.